{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:27:37Z","timestamp":1793111257610,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente Funds; Prog. M3\/6 and M2\/5"],"award-info":[{"award-number":["Ricerca Corrente Funds; Prog. M3\/6 and M2\/5"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003852","name":"Regione Campania","doi-asserted-by":"publisher","award":["POR CAMPANIA FESR 2014\/2020; CUP: B61G18000470007"],"award-info":[{"award-number":["POR CAMPANIA FESR 2014\/2020; CUP: B61G18000470007"]}],"id":[{"id":"10.13039\/501100003852","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG17007"],"award-info":[{"award-number":["IG17007"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG19865"],"award-info":[{"award-number":["IG19865"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Fellowship 21113"],"award-info":[{"award-number":["Fellowship 21113"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Fellowship 22648"],"award-info":[{"award-number":["Fellowship 22648"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["Fellowship 19586"],"award-info":[{"award-number":["Fellowship 19586"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["2017HWTP2K"],"award-info":[{"award-number":["2017HWTP2K"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Despite the introduction of several novel therapeutic approaches that improved survival, metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease. Herein we report the synergistic antitumor interaction between two well-known drugs used for years in clinical practice, the antiepileptic agent with histone deacetylase inhibitory activity valproic acid and the cholesterol lowering agent simvastatin, in mCRPC models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Synergistic anti-tumor effect was assessed on PC3, 22Rv1, DU145, DU145R80, LNCaP prostate cancer cell lines and EPN normal prostate epithelial cells, by calculating combination index (CI), caspase 3\/7 activation and colony formation assays as well as on tumor spheroids and microtissues scored with luminescence 3D-cell viability assay. Cancer stem cells (CSC) compartment was studied evaluating specific markers by RT-PCR, western blotting and flow cytometry as well as by limiting dilution assay. Cholesterol content was evaluated by <jats:sup>1<\/jats:sup>H-NMR. Overexpression of wild-type YAP and constitutively active YAP5SA were obtained by lipofectamine-based transfection and evaluated by immunofluorescence, western blotting and RT-PCR. 22Rv1 R_39 docetaxel resistant cells were selected by stepwise exposure to increasing drug concentrations. In vivo experiments were performed on xenograft models of DU145R80, 22Rv1 parental and docetaxel resistant cells, in athymic mice.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We demonstrated the capacity of the combined approach to target CSC compartment by a novel molecular mechanism based on the inhibition of YAP oncogene via concurrent modulation of mevalonate pathway and AMPK. Because both CSCs and YAP activation have been associated with chemo-resistance, we tested if the combined approach can potentiate docetaxel, a standard of care in mCRCP treatment. Indeed, we demonstrated, both in vitro and in vivo models, the ability of valproic acid\/simvastatin combination to sensitize mCRPC cells to docetaxel and to revert docetaxel-resistance, by mevalonate pathway\/YAP axis modulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Overall, mCRPC progression and therapeutic resistance driven by CSCs via YAP, can be tackled by the combined repurposing of two generic and safe drugs, an approach that warrants further clinical development in this disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-020-01723-7","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T12:03:07Z","timestamp":1602158587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":57,"title":["Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition"],"prefix":"10.1186","volume":"39","author":[{"given":"Federica","family":"Iannelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Serena","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Lombardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Ciardiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Grumetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"De Rienzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Moccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Vitagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sorice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Costantini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rita","family":"Milone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Pucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Di Gennaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gennaro","family":"Ciliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-6053","authenticated-orcid":false,"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"issue":"Suppl 5","key":"1723_CR1","doi-asserted-by":"publisher","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","volume":"26","author":"C Parker","year":"2015","unstructured":"Parker C, Gillessen S, Heidenreich A, Horwich A, Committee EG. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v69\u201377.","journal-title":"Ann Oncol"},{"issue":"6","key":"1723_CR2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1723_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.ejca.2016.04.002","volume":"61","author":"G Roviello","year":"2016","unstructured":"Roviello G, Sigala S, Sandhu S, Bonetta A, Cappelletti MR, Zanotti L, et al. Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: a literature based meta-analysis of randomized trials. Eur J Cancer. 2016;61:111\u201321.","journal-title":"Eur J Cancer"},{"issue":"11","key":"1723_CR4","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137.","journal-title":"J Clin Oncol"},{"key":"1723_CR5","doi-asserted-by":"publisher","first-page":"5416923","DOI":"10.1155\/2018\/5416923","volume":"2018","author":"LTH Phi","year":"2018","unstructured":"Phi LTH, Sari IN, Yang YG, Lee SH, Jun N, Kim KS, et al. Cancer stem cells (CSCs) in drug resistance and their therapeutic implications in cancer treatment. Stem Cells Int. 2018;2018:5416923.","journal-title":"Stem Cells Int"},{"issue":"1","key":"1723_CR6","doi-asserted-by":"publisher","first-page":"2897","DOI":"10.1038\/s41467-018-05220-6","volume":"9","author":"AS Cazet","year":"2018","unstructured":"Cazet AS, Hui MN, Elsworth BL, Wu SZ, Roden D, Chan CL, et al. Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer. Nat Commun. 2018;9(1):2897.","journal-title":"Nat Commun"},{"issue":"9","key":"1723_CR7","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1111\/j.1464-410X.2005.05744.x","volume":"96","author":"NJ Maitland","year":"2005","unstructured":"Maitland NJ, Collins A. A tumour stem cell hypothesis for the origins of prostate cancer. BJU Int. 2005;96(9):1219\u201323.","journal-title":"BJU Int"},{"issue":"1","key":"1723_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1158\/0008-5472.CAN-19-1169","volume":"80","author":"CJ Libby","year":"2020","unstructured":"Libby CJ, McConathy J, Darley-Usmar V, Hjelmeland AB. The role of metabolic plasticity in blood and brain stem cell pathophysiology. Cancer Res. 2020;80(1):5\u201316.","journal-title":"Cancer Res"},{"key":"1723_CR9","doi-asserted-by":"crossref","unstructured":"Roca MS, Di Gennaro E, Budillon A. Implication for cancer stem cells in solid cancer chemo-resistance: promising therapeutic strategies based on the use of HDAC inhibitors. J Clin Med. 2019;8(7):912.","DOI":"10.3390\/jcm8070912"},{"key":"1723_CR10","doi-asserted-by":"crossref","unstructured":"Frame FM, Maitland NJ. Epigenetic control of gene expression in the Normal and malignant human prostate: a rapid response which promotes therapeutic resistance. Int J Mol Sci. 2019;20(10):2437.","DOI":"10.3390\/ijms20102437"},{"issue":"6","key":"1723_CR11","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.coph.2012.07.006","volume":"12","author":"K Pelton","year":"2012","unstructured":"Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol. 2012;12(6):751\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"11","key":"1723_CR12","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1038\/nrc.2016.76","volume":"16","author":"PJ Mullen","year":"2016","unstructured":"Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay between cell signalling and the mevalonate pathway in cancer. Nat Rev Cancer. 2016;16(11):718\u201331.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1723_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1574892812666171129141211","volume":"13","author":"F Iannelli","year":"2018","unstructured":"Iannelli F, Lombardi R, Milone MR, Pucci B, De Rienzo S, Budillon A, et al. Targeting Mevalonate pathway in cancer treatment: repurposing of statins. Recent Pat Anticancer Drug Discov. 2018;13(2):184\u2013200.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"5","key":"1723_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.221","volume":"8","author":"SM Lacher","year":"2017","unstructured":"Lacher SM, Bruttger J, Kalt B, Berthelet J, Rajalingam K, Wortge S, et al. HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival. Cell Death Dis. 2017;8(5):e2824.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1723_CR15","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/1055-9965.EPI-15-0631","volume":"25","author":"EH Allott","year":"2016","unstructured":"Allott EH, Farnan L, Steck SE, Arab L, Su LJ, Mishel M, et al. Statin use and prostate cancer aggressiveness: results from the population-based North Carolina-Louisiana prostate cancer project. Cancer Epidemiol Biomarkers Prev. 2016;25(4):670\u20137.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"1723_CR16","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/nrurol.2016.199","volume":"14","author":"MA Alfaqih","year":"2017","unstructured":"Alfaqih MA, Allott EH, Hamilton RJ, Freeman MR, Freedland SJ. The current evidence on statin use and prostate cancer prevention: are we there yet? Nat Rev Urol. 2017;14(2):107\u201319.","journal-title":"Nat Rev Urol"},{"issue":"5","key":"1723_CR17","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1758834016647962","volume":"8","author":"MT Schweizer","year":"2016","unstructured":"Schweizer MT, Yu EY. Targeting intratumoral androgens: statins and beyond. Ther Adv Med Oncol. 2016;8(5):388\u201395.","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"1723_CR18","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"B Huang","year":"2020","unstructured":"Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132\u201341.","journal-title":"Nat Metab"},{"issue":"37","key":"1723_CR19","doi-asserted-by":"publisher","first-page":"14328","DOI":"10.1074\/jbc.RA118.004442","volume":"293","author":"Y Kong","year":"2018","unstructured":"Kong Y, Cheng L, Mao F, Zhang Z, Zhang Y, Farah E, et al. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). J Biol Chem. 2018;293(37):14328\u201341.","journal-title":"J Biol Chem"},{"issue":"2","key":"1723_CR20","first-page":"151","volume":"13","author":"X Chen","year":"2016","unstructured":"Chen X, Liu Y, Wu J, Huang H, Du Z, Zhang K, et al. Mechanistic study of inhibitory effects of atorvastatin and Docetaxel in combination on prostate cancer. Cancer Genomics Proteomics. 2016;13(2):151\u201360.","journal-title":"Cancer Genomics Proteomics"},{"issue":"11","key":"1723_CR21","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.1158\/1535-7163.MCT-09-0254","volume":"8","author":"F Bruzzese","year":"2009","unstructured":"Bruzzese F, Rocco M, Castelli S, Di Gennaro E, Desideri A, Budillon A. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis. Mol Cancer Ther. 2009;8(11):3075\u201387.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"1723_CR22","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1038\/sj.bjc.6605969","volume":"103","author":"E Di Gennaro","year":"2010","unstructured":"Di Gennaro E, Piro G, Chianese MI, Franco R, Di Cintio A, Moccia T, et al. Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. Br J Cancer. 2010;103(11):1680\u201391.","journal-title":"Br J Cancer"},{"issue":"2","key":"1723_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2174\/157489207780832450","volume":"2","author":"A Budillon","year":"2007","unstructured":"Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M. Histone deacetylase inhibitors: a new wave of molecular targeted anticancer agents. Recent Pat Anticancer Drug Discov. 2007;2(2):119\u201334.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"8","key":"1723_CR24","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1158\/1535-7163.MCT-18-1117","volume":"18","author":"G Piro","year":"2019","unstructured":"Piro G, Roca MS, Bruzzese F, Carbone C, Iannelli F, Leone A, et al. Vorinostat potentiates 5-fluorouracil\/Cisplatin combination by inhibiting chemotherapy-induced EGFR nuclear translocation and increasing Cisplatin uptake. Mol Cancer Ther. 2019;18(8):1405\u201317.","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"1723_CR25","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","volume":"12","author":"BS Mann","year":"2007","unstructured":"Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247\u201352.","journal-title":"Oncologist."},{"issue":"7","key":"1723_CR26","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1586\/era.10.88","volume":"10","author":"C Grant","year":"2010","unstructured":"Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, et al. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10(7):997\u20131008.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"1723_CR27","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1177\/2040620715592567","volume":"6","author":"A Sawas","year":"2015","unstructured":"Sawas A, Radeski D, O'Connor OA. Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review. Ther Adv Hematol. 2015;6(4):202\u20138.","journal-title":"Ther Adv Hematol"},{"issue":"5","key":"1723_CR28","first-page":"296","volume":"41","author":"D Moore","year":"2016","unstructured":"Moore D. Panobinostat (Farydak): a novel option for the treatment of relapsed or relapsed and refractory multiple myeloma. P T. 2016;41(5):296\u2013300.","journal-title":"P T"},{"issue":"7","key":"1723_CR29","doi-asserted-by":"publisher","first-page":"7715","DOI":"10.18632\/oncotarget.6802","volume":"7","author":"M Terranova-Barberio","year":"2016","unstructured":"Terranova-Barberio M, Roca MS, Zotti AI, Leone A, Bruzzese F, Vitagliano C, et al. Valproic acid potentiates the anticancer activity of capecitabine in vitro and in vivo in breast cancer models via induction of thymidine phosphorylase expression. Oncotarget. 2016;7(7):7715\u201331.","journal-title":"Oncotarget."},{"key":"1723_CR30","doi-asserted-by":"crossref","unstructured":"Salem O, Hansen CG. The hippo pathway in prostate cancer. Cells. 2019;8(4):370.","DOI":"10.3390\/cells8040370"},{"key":"1723_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.406","volume":"4","author":"F Bruzzese","year":"2013","unstructured":"Bruzzese F, Pucci B, Milone MR, Ciardiello C, Franco R, Chianese MI, et al. Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. Cell Death Dis. 2013;4:e878.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1723_CR32","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s13046-017-0647-5","volume":"36","author":"M Terranova-Barberio","year":"2017","unstructured":"Terranova-Barberio M, Pecori B, Roca MS, Imbimbo S, Bruzzese F, Leone A, et al. Synergistic antitumor interaction between valproic acid, capecitabine and radiotherapy in colorectal cancer: critical role of p53. J Exp Clin Cancer Res. 2017;36(1):177.","journal-title":"J Exp Clin Cancer Res"},{"key":"1723_CR33","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.mex.2015.11.001","volume":"2","author":"S Baghirova","year":"2015","unstructured":"Baghirova S, Hughes BG, Hendzel MJ, Schulz R. Sequential fractionation and isolation of subcellular proteins from tissue or cultured cells. MethodsX. 2015;2:440\u20135.","journal-title":"MethodsX."},{"issue":"15","key":"1723_CR34","doi-asserted-by":"publisher","first-page":"19559","DOI":"10.18632\/oncotarget.7195","volume":"7","author":"C Ciardiello","year":"2016","unstructured":"Ciardiello C, Roca MS, Noto A, Bruzzese F, Moccia T, Vitagliano C, et al. Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression. Oncotarget. 2016;7(15):19559\u201374.","journal-title":"Oncotarget."},{"issue":"32","key":"1723_CR35","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1038\/onc.2017.212","volume":"36","author":"A Noto","year":"2017","unstructured":"Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, et al. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP\/TAZ. Oncogene. 2017;36(32):4671\u20132.","journal-title":"Oncogene."},{"issue":"1","key":"1723_CR36","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41598-018-37546-y","volume":"9","author":"N Ruocco","year":"2019","unstructured":"Ruocco N, Annunziata C, Ianora A, Libralato G, Manfra L, Costantini S, et al. Toxicity of diatom-derived polyunsaturated aldehyde mixtures on sea urchin Paracentrotus lividus development. Sci Rep. 2019;9(1):517.","journal-title":"Sci Rep"},{"issue":"W1","key":"1723_CR37","doi-asserted-by":"publisher","first-page":"W251","DOI":"10.1093\/nar\/gkv380","volume":"43","author":"J Xia","year":"2015","unstructured":"Xia J, Sinelnikov IV, Han B, Wishart DS. MetaboAnalyst 3.0--making metabolomics more meaningful. Nucleic Acids Res. 2015;43(W1):W251\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1723_CR38","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1038\/cdd.2014.37","volume":"21","author":"S Colak","year":"2014","unstructured":"Colak S, Zimberlin CD, Fessler E, Hogdal L, Prasetyanti PR, Grandela CM, et al. Decreased mitochondrial priming determines chemoresistance of colon cancer stem cells. Cell Death Differ. 2014;21(7):1170\u20137.","journal-title":"Cell Death Differ"},{"key":"1723_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.165","volume":"4","author":"MR Milone","year":"2013","unstructured":"Milone MR, Pucci B, Bruzzese F, Carbone C, Piro G, Costantini S, et al. Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells. Cell Death Dis. 2013;4:e641.","journal-title":"Cell Death Dis"},{"key":"1723_CR40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.biocel.2019.01.002","volume":"108","author":"CD Costa","year":"2019","unstructured":"Costa CD, Justo AA, Kobayashi PE, Story MM, Palmieri C, Laufer Amorim R, et al. Characterization of OCT3\/4, nestin, NANOG, CD44 and CD24 as stem cell markers in canine prostate cancer. Int J Biochem Cell Biol. 2019;108:21\u20138.","journal-title":"Int J Biochem Cell Biol"},{"issue":"8","key":"1723_CR41","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s00109-019-01807-8","volume":"97","author":"F Chen","year":"2019","unstructured":"Chen F, Chen X, Ren Y, Weng G, Keng PC, Chen Y, et al. Radiation-induced glucocorticoid receptor promotes CD44+ prostate cancer stem cell growth through activation of SGK1-Wnt\/beta-catenin signaling. J Mol Med (Berl). 2019;97(8):1169\u201382.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"1723_CR42","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s12253-016-0169-z","volume":"23","author":"E Kalantari","year":"2017","unstructured":"Kalantari E, Asgari M, Nikpanah S, Salarieh N, Asadi Lari MH, Madjd Z. Co-expression of putative cancer stem cell markers CD44 and CD133 in prostate carcinomas. Pathol Oncol Res. 2017;23(4):793\u2013802.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"1723_CR43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1186\/s12885-018-4344-3","volume":"18","author":"M Wei","year":"2018","unstructured":"Wei M, Mao S, Lu G, Li L, Lan X, Huang Z, et al. Valproic acid sensitizes metformin-resistant human renal cell carcinoma cells by upregulating H3 acetylation and EMT reversal. BMC Cancer. 2018;18(1):434.","journal-title":"BMC Cancer"},{"issue":"10","key":"1723_CR44","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1158\/1535-7163.MCT-14-0451","volume":"13","author":"MA Babcook","year":"2014","unstructured":"Babcook MA, Shukla S, Fu P, Vazquez EJ, Puchowicz MA, Molter JP, et al. Synergistic simvastatin and metformin combination chemotherapy for osseous metastatic castration-resistant prostate cancer. Mol Cancer Ther. 2014;13(10):2288\u2013302.","journal-title":"Mol Cancer Ther"},{"issue":"19 Pt B","key":"1723_CR45","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1016\/j.febslet.2015.08.009","volume":"589","author":"A Gonneaud","year":"2015","unstructured":"Gonneaud A, Turgeon N, Boisvert FM, Boudreau F, Asselin C. Loss of histone deacetylase Hdac1 disrupts metabolic processes in intestinal epithelial cells. FEBS Lett. 2015;589(19 Pt B):2776\u201383.","journal-title":"FEBS Lett"},{"issue":"4","key":"1723_CR46","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/ncb2936","volume":"16","author":"G Sorrentino","year":"2014","unstructured":"Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, et al. Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol. 2014;16(4):357\u201366.","journal-title":"Nat Cell Biol"},{"key":"1723_CR47","doi-asserted-by":"crossref","unstructured":"Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C, et al. YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine. Nutrients. 2016;8(10):546.","DOI":"10.3390\/nu8100546"},{"issue":"2","key":"1723_CR48","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.celrep.2014.09.036","volume":"9","author":"M DeRan","year":"2014","unstructured":"DeRan M, Yang J, Shen CH, Peters EC, Fitamant J, Chan P, et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 2014;9(2):495\u2013503.","journal-title":"Cell Rep"},{"issue":"6","key":"1723_CR49","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.neo.2018.03.006","volume":"20","author":"C Philippe","year":"2018","unstructured":"Philippe C, Pinson B, Dompierre J, Pantesco V, Viollet B, Daignan-Fornier B, et al. AICAR Antiproliferative properties involve the AMPK-independent activation of the tumor suppressors LATS 1 and 2. Neoplasia. 2018;20(6):555\u201362.","journal-title":"Neoplasia."},{"issue":"11","key":"1723_CR50","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1101\/gad.1903310","volume":"24","author":"I Lian","year":"2010","unstructured":"Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, et al. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev. 2010;24(11):1106\u201318.","journal-title":"Genes Dev"},{"issue":"1","key":"1723_CR51","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.yexcr.2018.07.041","volume":"371","author":"B Yan","year":"2018","unstructured":"Yan B, Jiang Z, Cheng L, Chen K, Zhou C, Sun L, et al. Paracrine HGF\/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP\/HIF-1alpha. Exp Cell Res. 2018;371(1):63\u201371.","journal-title":"Exp Cell Res"},{"key":"1723_CR52","doi-asserted-by":"crossref","unstructured":"McKee C, Brown C, Chaudhry GR. Self-assembling scaffolds supported long-term growth of human primed embryonic stem cells and Upregulated Core and naive pluripotent markers. Cells. 2019;8(12):1650.","DOI":"10.3390\/cells8121650"},{"issue":"20 Pt 1","key":"1723_CR53","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1158\/1078-0432.CCR-06-0443","volume":"12","author":"JD Wu","year":"2006","unstructured":"Wu JD, Haugk K, Coleman I, Woodke L, Vessella R, Nelson P, et al. Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors. Clin Cancer Res. 2006;12(20 Pt 1):6153\u201360.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1723_CR54","doi-asserted-by":"publisher","first-page":"946","DOI":"10.18632\/oncotarget.5834","volume":"7","author":"JE Stine","year":"2016","unstructured":"Stine JE, Guo H, Sheng X, Han X, Schointuch MN, Gilliam TP, et al. The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer. Oncotarget. 2016;7(1):946\u201360.","journal-title":"Oncotarget."},{"key":"1723_CR55","first-page":"2713","volume":"7","author":"M Harada","year":"2012","unstructured":"Harada M, Iwata C, Saito H, Ishii K, Hayashi T, Yashiro M, et al. NC-6301, a polymeric micelle rationally optimized for effective release of docetaxel, is potent but is less toxic than native docetaxel in vivo. Int J Nanomedicine. 2012;7:2713\u201327.","journal-title":"Int J Nanomedicine"},{"issue":"1","key":"1723_CR56","doi-asserted-by":"publisher","first-page":"5138","DOI":"10.1038\/s41467-018-07590-3","volume":"9","author":"SY Jiang","year":"2018","unstructured":"Jiang SY, Li H, Tang JJ, Wang J, Luo J, Liu B, et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat Commun. 2018;9(1):5138.","journal-title":"Nat Commun"},{"issue":"12","key":"1723_CR57","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","volume":"78","author":"Z Zhang","year":"2018","unstructured":"Zhang Z, Cheng L, Li J, Farah E, Atallah NM, Pascuzzi PE, et al. Inhibition of the Wnt\/beta-catenin pathway overcomes resistance to Enzalutamide in castration-resistant prostate cancer. Cancer Res. 2018;78(12):3147\u201362.","journal-title":"Cancer Res"},{"issue":"2","key":"1723_CR58","first-page":"238","volume":"6","author":"CC Chen","year":"2016","unstructured":"Chen CC, Hsieh TF, Huang CP, Yu AL, Chang WL, Shyr CR. Androgen receptor expands the population of cancer stem cells in upper urinary tract urothelial cell carcinoma cells. Am J Cancer Res. 2016;6(2):238\u201348.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"1723_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130118","volume":"10","author":"R Portillo-Lara","year":"2015","unstructured":"Portillo-Lara R, Alvarez MM. Enrichment of the cancer stem phenotype in sphere cultures of prostate cancer cell lines occurs through activation of developmental pathways mediated by the transcriptional regulator DeltaNp63alpha. PLoS One. 2015;10(6):e0130118.","journal-title":"PLoS One"},{"issue":"4","key":"1723_CR60","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.tcb.2015.11.004","volume":"26","author":"G Santinon","year":"2016","unstructured":"Santinon G, Pocaterra A, Dupont S. Control of YAP\/TAZ activity by metabolic and nutrient-sensing pathways. Trends Cell Biol. 2016;26(4):289\u201399.","journal-title":"Trends Cell Biol"},{"issue":"18","key":"1723_CR61","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/s41388-018-0141-3","volume":"37","author":"R Mancini","year":"2018","unstructured":"Mancini R, Noto A, Pisanu ME, De Vitis C, Maugeri-Sacca M, Ciliberto G. Metabolic features of cancer stem cells: the emerging role of lipid metabolism. Oncogene. 2018;37(18):2367\u201378.","journal-title":"Oncogene."},{"issue":"10","key":"1723_CR62","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-018-0158-8","volume":"24","author":"F Zanconato","year":"2018","unstructured":"Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A, et al. Transcriptional addiction in cancer cells is mediated by YAP\/TAZ through BRD4. Nat Med. 2018;24(10):1599\u2013610.","journal-title":"Nat Med"},{"issue":"70","key":"1723_CR63","doi-asserted-by":"publisher","first-page":"115054","DOI":"10.18632\/oncotarget.23014","volume":"8","author":"N Jiang","year":"2017","unstructured":"Jiang N, Ke B, Hjort-Jensen K, Iglesias-Gato D, Wang Z, Chang P, et al. YAP1 regulates prostate cancer stem cell-like characteristics to promote castration resistant growth. Oncotarget. 2017;8(70):115054\u201367.","journal-title":"Oncotarget."},{"key":"1723_CR64","doi-asserted-by":"crossref","unstructured":"Lai CJ, Lin CY, Liao WY, Hour TC, Wang HD, Chuu CP. CD44 promotes migration and invasion of Docetaxel-resistant prostate cancer cells likely via induction of hippo-yap signaling. Cells. 2019;8(4):295.","DOI":"10.3390\/cells8040295"},{"issue":"8","key":"1723_CR65","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1128\/MCB.00102-15","volume":"35","author":"L Zhang","year":"2015","unstructured":"Zhang L, Yang S, Chen X, Stauffer S, Yu F, Lele SM, et al. The hippo pathway effector YAP regulates motility, invasion, and castration-resistant growth of prostate cancer cells. Mol Cell Biol. 2015;35(8):1350\u201362.","journal-title":"Mol Cell Biol"},{"issue":"3","key":"1723_CR66","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4103\/aja.aja_72_18","volume":"21","author":"CJ Lin","year":"2019","unstructured":"Lin CJ, Lo UG, Hsieh JT. The regulatory pathways leading to stem-like cells underlie prostate cancer progression. Asian J Androl. 2019;21(3):233\u201340.","journal-title":"Asian J Androl"},{"issue":"7","key":"1723_CR67","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1002\/stem.1122","volume":"30","author":"C Ginestier","year":"2012","unstructured":"Ginestier C, Monville F, Wicinski J, Cabaud O, Cervera N, Josselin E, et al. Mevalonate metabolism regulates basal breast cancer stem cells and is a potential therapeutic target. Stem Cells. 2012;30(7):1327\u201337.","journal-title":"Stem Cells"},{"issue":"3","key":"1723_CR68","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1039\/C5MB00554J","volume":"12","author":"Z Lin","year":"2016","unstructured":"Lin Z, Bishop KS, Sutherland H, Marlow G, Murray P, Denny WA, et al. A quinazoline-based HDAC inhibitor affects gene expression pathways involved in cholesterol biosynthesis and mevalonate in prostate cancer cells. Mol Biosyst. 2016;12(3):839\u201349.","journal-title":"Mol Biosyst"},{"issue":"5","key":"1723_CR69","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.cancergen.2015.03.008","volume":"208","author":"H Karlic","year":"2015","unstructured":"Karlic H, Thaler R, Gerner C, Grunt T, Proestling K, Haider F, et al. Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells. Cancer Genet. 2015;208(5):241\u201352.","journal-title":"Cancer Genet"},{"issue":"11","key":"1723_CR70","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.1158\/1535-7163.MCT-07-0221","volume":"6","author":"J Sonnemann","year":"2007","unstructured":"Sonnemann J, Bumbul B, Beck JF. Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro. Mol Cancer Ther. 2007;6(11):2976\u201384.","journal-title":"Mol Cancer Ther"},{"key":"1723_CR71","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ebiom.2016.07.019","volume":"10","author":"TT Wei","year":"2016","unstructured":"Wei TT, Lin YT, Chen WS, Luo P, Lin YC, Shun CT, et al. Dual targeting of 3-Hydroxy-3-methylglutaryl coenzyme a Reductase and histone Deacetylase as a therapy for colorectal cancer. EBioMedicine. 2016;10:124\u201336.","journal-title":"EBioMedicine."},{"key":"1723_CR72","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.biocel.2017.10.003","volume":"92","author":"YL Chang","year":"2017","unstructured":"Chang YL, Huang LC, Chen YC, Wang YW, Hueng DY, Huang SM. The synergistic effects of valproic acid and fluvastatin on apoptosis induction in glioblastoma multiforme cell lines. Int J Biochem Cell Biol. 2017;92:155\u201363.","journal-title":"Int J Biochem Cell Biol"},{"key":"1723_CR73","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.ejphar.2017.08.022","volume":"813","author":"X Kou","year":"2017","unstructured":"Kou X, Yang Y, Jiang X, Liu H, Sun F, Wang X, et al. Vorinostat and simvastatin have synergistic effects on triple-negative breast cancer cells via abrogating Rab7 prenylation. Eur J Pharmacol. 2017;813:161\u201371.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"1723_CR74","doi-asserted-by":"publisher","first-page":"17833","DOI":"10.18632\/oncotarget.14868","volume":"8","author":"Z Lin","year":"2017","unstructured":"Lin Z, Zhang Z, Jiang X, Kou X, Bao Y, Liu H, et al. Mevastatin blockade of autolysosome maturation stimulates LBH589-induced cell death in triple-negative breast cancer cells. Oncotarget. 2017;8(11):17833\u201348.","journal-title":"Oncotarget."},{"issue":"7","key":"1723_CR75","doi-asserted-by":"publisher","first-page":"5324","DOI":"10.18632\/oncotarget.2694","volume":"6","author":"MR Milone","year":"2015","unstructured":"Milone MR, Pucci B, Bifulco K, Iannelli F, Lombardi R, Ciardiello C, et al. Proteomic analysis of zoledronic-acid resistant prostate cancer cells unveils novel pathways characterizing an invasive phenotype. Oncotarget. 2015;6(7):5324\u201341.","journal-title":"Oncotarget."},{"issue":"5","key":"1723_CR76","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s10552-016-0737-2","volume":"27","author":"JK Salminen","year":"2016","unstructured":"Salminen JK, Tammela TL, Auvinen A, Murtola TJ. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study. Cancer Causes Control. 2016;27(5):637\u201345.","journal-title":"Cancer Causes Control"},{"issue":"50","key":"1723_CR77","doi-asserted-by":"publisher","first-page":"6414","DOI":"10.1038\/s41388-018-0419-5","volume":"37","author":"H Han","year":"2018","unstructured":"Han H, Yang B, Nakaoka HJ, Yang J, Zhao Y, Le Nguyen K, et al. Hippo signaling dysfunction induces cancer cell addiction to YAP. Oncogene. 2018;37(50):6414\u201324.","journal-title":"Oncogene."},{"issue":"15","key":"1723_CR78","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","volume":"351","author":"DP Petrylak","year":"2004","unstructured":"Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513\u201320.","journal-title":"N Engl J Med"},{"issue":"2","key":"1723_CR79","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40610-018-0095-9","volume":"4","author":"K Ruggero","year":"2018","unstructured":"Ruggero K, Farran-Matas S, Martinez-Tebar A, Aytes A. Epigenetic regulation in prostate cancer progression. Curr Mol Biol Rep. 2018;4(2):101\u201315.","journal-title":"Curr Mol Biol Rep"},{"issue":"6","key":"1723_CR80","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1177\/1756287215597637","volume":"7","author":"D Kaushik","year":"2015","unstructured":"Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF. Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol. 2015;7(6):388\u201395.","journal-title":"Ther Adv Urol"},{"key":"1723_CR81","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1186\/1471-2407-14-875","volume":"14","author":"A Avallone","year":"2014","unstructured":"Avallone A, Piccirillo MC, Delrio P, Pecori B, Di Gennaro E, Aloj L, et al. Phase 1\/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid--short radiotherapy--rectum 3rd trial). BMC Cancer. 2014;14:875.","journal-title":"BMC Cancer"},{"issue":"1","key":"1723_CR82","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1186\/s12885-016-2957-y","volume":"16","author":"F Caponigro","year":"2016","unstructured":"Caponigro F, Di Gennaro E, Ionna F, Longo F, Aversa C, Pavone E, et al. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and\/or metastatic squamous cell carcinoma of head and neck-V-CHANCE trial. BMC Cancer. 2016;16(1):918.","journal-title":"BMC Cancer"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-020-01723-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-020-01723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T23:52:03Z","timestamp":1633650723000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-020-01723-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1723"],"URL":"https:\/\/doi.org\/10.1186\/s13046-020-01723-7","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The experimental protocols for in vivo mice studies were approved by the Italian Ministry of Health.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All Authors have seen and approved the manuscript and consent publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"213"}}